{"organizations": [], "uuid": "e83c5ab844ce3144a63d3b2c0bbd1fa78288f04c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180426.html", "section_title": "Archive News &amp; Video for Thursday, 26 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-grants-breakthrough-therapy-de/brief-fda-grants-breakthrough-therapy-designation-to-omeros-masp-2-inhibitor-oms721-idUSASO0003WZ", "country": "US", "domain_rank": 408, "title": "FDA Grants Breakthrough Therapy Designation To Omeros' Masp-2 Inhibitor Oms721", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.885, "site_type": "news", "published": "2018-04-27T03:02:00.000+03:00", "replies_count": 0, "uuid": "e83c5ab844ce3144a63d3b2c0bbd1fa78288f04c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-grants-breakthrough-therapy-de/brief-fda-grants-breakthrough-therapy-designation-to-omeros-masp-2-inhibitor-oms721-idUSASO0003WZ", "ord_in_thread": 0, "title": "FDA Grants Breakthrough Therapy Designation To Omeros' Masp-2 Inhibitor Oms721", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "omeros corp", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 26 (Reuters) - Omeros Corp:\n* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO OMEROSâ€™ MASP-2 INHIBITOR OMS721 FOR THE TREATMENT OF HIGH-RISK HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY\n* DISCUSSIONS ONGOING WITH FDA AND EUROPEAN REGULATORS FOR EXPEDITED APPROVAL OF OMS721 Source text for Eikon:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-27T03:02:00.000+03:00", "crawled": "2018-04-27T17:15:18.012+03:00", "highlightTitle": ""}